Overview

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Aerie Pharmaceuticals
Treatments:
Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions